The Scientific Research and Experimental Development (SR&ED) tax credit program is undergoing some of its most significant and beneficial transformations in over a decade. Announced in the recent Fall Economic Statement and Federal Budget, these enhancements are designed to inject billions of dollars into Canada’s innovation ecosystem, making the program more accessible and lucrative for businesses of all sizes.
Key Enhancements for 2024 and 2025
If your company performs R&D in Canada, these structural changes could drastically improve your cash flow and net return on innovation investments.
1. Increased Expenditure Limits for CCPCs
The most substantial change for Canadian-Controlled Private Corporations (CCPCs) is the massive increase in the annual expenditure limit eligible for the enhanced 35% refundable Investment Tax Credit (ITC). Previously capped at $3 million, this limit has been raised to $6 million. This expansion allows qualifying CCPCs to claim up to $2.1 million in refundable credits annually, effectively doubling the cash-flow potential for R&D-intensive businesses.
2. The Return of Capital Expenditures
Reversing a restrictive policy implemented in 2012/2014, capital expenditures are once again eligible for both deductions against income and investment tax credits under the SR&ED program. This applies to property acquired (or lease costs incurred) on or after December 16, 2024. For companies investing in expensive R&D lab equipment, prototyping machinery, or specialized testing apparatuses, this is a monumental capital recovery opportunity.
3. Expanded Eligibility to Public Corporations
For the primary time, "eligible Canadian public corporations" (ECPCs) can now qualify for the enhanced 35% refundable tax credit, rather than being restricted to the standard 15% non-refundable rate. ECPCs can access this enhanced rate on up to $6 million of qualifying SR&ED expenditures annually, subject to phase-out mechanisms based on average gross revenue.
Strategic Takeaways for Canadian Founders
These enhancements underscore the government’s commitment to retaining IP and deep-tech manufacturing within Canada. Given that the CRA is also rolling out AI-supported risk screening to accelerate low-risk claims, preparing robust, contemporaneous technical documentation is more critical than ever.
At Canadian Funding Partners Inc., our engineers and CPAs are already helping clients restructure their 2025 technological roadmaps to fully leverage these elevated limits and the reinstatement of capital expenditure eligibility. Book a consultation today to map your R&D pipeline against the new framework.